What is the revenue of DiaSorin?
DiaSorin reports multi-billion-euro equivalent revenues (surpassing €1.3 billion to €1.4 billion in annual tracking), underpinned by continuous global demand for specialized clinical laboratory diagnostics. The enterprise maintains robust financial stability through high-volume sales of immunoassay and molecular diagnostic instruments, specialized assay kits, and comprehensive clinical testing services provided to hospitals, commercial reference labs, and research institutions worldwide.
Related FAQs
Yes, DiaSorin officially acquired Luminex Corporation in 2021 for approximately $1.8 billion.
Yes, Diasorin is a global leader in the biotechnology and diagnostic sector. The company specializes in the development, production, and commercialization of diagnostic tests for a wide range of clinical conditions.
Yes, DiaSorin S.p.A. is a public company. Its shares are listed and traded on the Borsa Italiana (the Italian Stock Exchange) under the ticker symbol "DIA.
The official operational and laboratory facility address for Diasorin Molecular LLC in Austin, Texas, is located at 12112 Technology Blvd, Suite 130, Austin, TX 78727.
Telenor ASA generates annual revenues approaching NOK 77 billion (translating to approximately $7.2 billion to $7.
Citrix Systems, operating as a core component under private equity ownership and cloud software consolidation strategies, historically generated annual revenues approaching $3 billion to $3.2 billion USD.
DiaSorin S.p.A. is a multinational Italian biotechnology company that operates as a global leader in the field of immunodiagnostics and molecular diagnostics.
The DiaSorin LIAISON® XL is a sophisticated, fully automated immunoassay analyzer engineered for high-throughput clinical and research laboratories.
DiaSorin S.p.A. generates annual revenues of approximately $1.40 billion USD, reflecting its strong global presence as a multinational biotechnology leader specializing in immunodiagnostic and molecular diagnostic testing solutions.
DiaSorin sells a comprehensive portfolio of medical diagnostic test kits, immunoassay reagents, molecular diagnostic assays, and fully automated laboratory instruments to hospitals, commercial reference laboratories, and research institutions worldwi...
DiaSorin is primarily classified as an in vitro diagnostics (IVD) company, which places it within the broader medical equipment and biotechnology sectors.
Market analysts are currently divided on Diasorin (DSR), with a consensus that leans toward "Hold" rather than a definitive buy or sell.
"DIC" can refer to multiple entities depending on the sector.
The proper noun and corporate name DiaSorin does not translate to a literal word in standard dictionaries, as it is a specialized corporate identity formed from a combination of terms associated with its medical diagnostic origins.
The DiaSorin LIAISON XL automated analyzer features a maximum analytical throughput of up to 180 tests per hour (with specific configurations running between 171 and 180 tests per hour depending on assay protocols), designed for high-volume random-ac...
Yes, DiaSorin is an Italian multinational company. It is headquartered in Saluggia, in the Piedmont region of Italy.
DiaSorin S.p.A. is a prominent global leader in the laboratory diagnostics market, specializing in immunodiagnostics and molecular diagnostics.